Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities
Amicus Therapeutics (FOLD) and Autoliv (ALV) present a puzzle for investors, as their quantitative ratings seemingly conflict with recent developments and underlying fundamentals. FOLD is navigating a proposed $4.7 billion acquisition by BioMarin, shifting its investment thesis from an independent innovator to an integrated asset. Meanwhile, Autoliv, a leader in automotive safety, faces industry cycles and competitive pressures, despite strong TTM financials and a 2.93% dividend yield. The article also briefly touches on Alvotech (ALVO), a biosimilar company, acknowledging a potential data error in its inclusion within the Autoliv discussion.
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves
This article reports on the Q1 2026 portfolio changes made by John Paulson's fund. The fund initiated a new position in Amicus Therapeutics and divested its holdings in SOLS. These moves reflect the fund's investment strategy and outlook for the respective companies.
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves
John Paulson's hedge fund, Paulson & Co., made significant changes to its portfolio in Q1. The fund initiated a new position in Amicus Therapeutics (FOLD) and completely exited its stake in SOLS Technology (SOLS). These moves reflect strategic adjustments in Paulson's investment focus.
Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake
Barclays PLC has reported a beneficial ownership of 17,755,672 shares of Amicus Therapeutics Inc (NASDAQ: FOLD), which constitutes a 5.65% stake in the company. The Schedule 13G filing indicates that Barclays holds sole voting power over 17,747,658 shares and shared voting power over 8,014 shares. This filing categorizes Barclays as an institutional investor with a passive investment intent.
Amicus Therapeutics stock (US03152W1099): Biotech focused on rare diseases
Amicus Therapeutics is a biotechnology company focused on rare metabolic diseases like Fabry and Pompe, with its lead product Galafold driving revenue growth. The company emphasizes orphan drug development, leveraging regulatory incentives and investing in R&D for next-generation therapies, including gene therapies. Listed on Nasdaq under FOLD, Amicus offers US investors exposure to the resilient rare disease sector, balancing high-growth potential with industry-inherent clinical risks.
Fabry Disease Treatment Market to Reach USD 3,530.5 Million
The global Fabry disease treatment market is projected to grow from USD 2,322.5 million in 2025 to USD 3,530.5 million by 2033, exhibiting a CAGR of 7.4%. This growth is driven by increasing awareness of rare genetic disorders, advancements in treatment modalities like enzyme replacement and gene therapies, and expanding diagnostic technologies. North America is expected to lead the market with a 45.1% share, while notable companies such as Sanofi, Takeda, and Amicus Therapeutics are key players in the industry.
FOLD SEC Filings - Amicus Therapeut 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Amicus Therapeutics (FOLD) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details recent significant events such as the withdrawal of FOLD's common stock listing from Nasdaq, the approval of its merger with BioMarin Pharmaceutical Inc., and insider stock sales. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.
FOLD SEC Filings - Amicus Therapeut 10-K, 10-Q, 8-K Forms
This page provides access to Amicus Therapeutics (FOLD) SEC filings, including 10-K, 10-Q, and 8-K reports, vital for investors and traders. Recent filings detail the company's acquisition by BioMarin for $14.50 per share, strong 2025 revenue growth primarily from Galafold and Pombiliti + Opfolda, and insider trading activities. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing
Amicus Therapeutics, Inc. has filed a Form 15-12G with the SEC, indicating the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports. This action follows the merger of Amicus Therapeutics with BioMarin Pharmaceutical Inc.'s wholly-owned subsidiary, making Amicus Therapeutics a fully-owned subsidiary of BioMarin. The filing specifies the common stock of Amicus Therapeutics, Inc. and was signed on May 7, 2026.
BioMarin beats estimates, raises guidance on Amicus deal
BioMarin Pharmaceutical Inc. exceeded analyst expectations in its first quarter, reporting adjusted EPS of $0.76 and revenue of $766 million. The company raised its full-year revenue and adjusted EPS guidance following the acquisition of Amicus Therapeutics, which added GALAFOLD and POMBILITI + OPFOLDA to its commercial portfolio, despite a slight dip in share price. Its Enzyme Therapies and VOXZOGO segments showed growth, contributing to a strong operating cash flow.
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD
UBS Group AG has significantly increased its stake in Amicus Therapeutics (NASDAQ: FOLD) by 240.5% in the fourth quarter, now holding 5,893,288 shares valued at approximately $83.92 million. Amicus Therapeutics shares are trading near a 12-month high, with a market cap of $4.55 billion, and analysts currently rate the stock as "Hold" with an average price target of $14.56. Despite insider selling by CEO Bradley L. Campbell, institutional investors continue to adjust their positions in the biopharmaceutical company.
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD
CM Management LLC reduced its stake in Amicus Therapeutics (FOLD) by 17.8% in Q4, but it still represents the fund's fourth-largest holding with a value of $5.27 million. Amicus Therapeutics missed quarterly EPS estimates ($0.10 vs. $0.13) despite a 23.7% year-over-year revenue increase to $185.21 million. The stock currently trades near its 12-month high with a market cap of approximately $4.55 billion, and analysts have a consensus "Hold" rating with an average target price of $14.56.
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD
Pictet Asset Management Holding SA significantly reduced its stake in Amicus Therapeutics by 70.6% in Q4, selling over 4.7 million shares. Meanwhile, Amicus Therapeutics CEO Bradley L. Campbell also sold 22,500 shares. Analysts currently have a consensus "Hold" rating for the stock, with an average target price of $15.39, while the company reported a Q4 EPS of $0.10, missing estimates.
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust
BioMarin Pharmaceutical has finalized its acquisition of Amicus Therapeutics (formerly NasdaqGM:FOLD), leading to Amicus's delisting from Nasdaq and removal from major indices such as the S&P and Russell families. This transaction integrates Amicus's rare disease portfolio into BioMarin and concludes Amicus's run as an independent public company. For investors, the focus now shifts to BioMarin's integration progress and the implications for sector exposure for those in biotech index funds.
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset
BioMarin Pharmaceutical has successfully acquired Amicus Therapeutics, expanding its rare disease portfolio with two new lysosomal storage disease treatments and an investigational kidney disease therapy. This acquisition aims to diversify BioMarin's revenue streams and strengthen its presence in rare genetic conditions and nephrology, while presenting integration challenges and increased operational costs. Investors will be watching for details on target setting, integration, and DMX-200 development.
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing
This article reports on an SEC filing (Form EFFECT) by Amicus Therapeutics, Inc. (FOLD). The filing, dated April 30, 2026, indicates a neutral impact and sentiment regarding the effectiveness of a previous submission. It details the SEC's Notice of Effectiveness with an effectiveness date of April 29, 2026.
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing
This article announces an SEC filing by Amicus Therapeutics, Inc. (FOLD) of form EFFECT, declared effective on April 29, 2026. The filing, with accession number 0001140361-26-016982, indicates a neutral impact and sentiment regarding the company. It also provides an overview of Amicus Therapeutics, including market data and recent news.
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday
Amicus Therapeutics (FOLD) is expected to release its Q1 2026 earnings before market open on Thursday, May 7th, with analysts projecting earnings of $0.0375 per share and revenue of $162.5060 million. The company's stock has a market capitalization of $4.55 billion and a P/E ratio of -181.13, trading near its 1-year high. Recent insider trading shows CEO Bradley L. Campbell selling 22,500 shares, while institutional investors have adjusted their positions.
Amicus Therapeutics, Inc. Financial Disclosures & Filings
This page provides access to Amicus Therapeutics, Inc.'s financial disclosures and regulatory filings. It lists various documents including quarterly and annual earnings releases, 10-K and 10-Q reports, call transcripts, presentation slides, and event transcripts from healthcare conferences for the years 2024 and 2025. The aim is to offer insights into the company's performance and strategy for informed investment decisions.
Vanguard Capital Management holds 5.20% of Amicus Therapeutics (NASDAQ: FOLD)
Vanguard Capital Management has reported a beneficial ownership of 16,350,837 shares, representing a 5.20% stake in Amicus Therapeutics (NASDAQ: FOLD) as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. Vanguard holds sole dispositive power over all these shares and sole voting power over 2,327,280 shares.
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust
BioMarin Pharmaceutical has finalized its acquisition of Amicus Therapeutics (NasdaqGM:FOLD), leading to Amicus's delisting from Nasdaq and removal from major indices like S&P and Russell. This transaction marks the end of Amicus as an independent public entity, integrating its rare disease portfolio into BioMarin and shifting investment focus. Investors are advised to consider how this change affects sector exposure and portfolio concentration, especially those tracking biotech indices or using index funds.
Net current asset value per share of Amicus Therapeutics, Inc. – BIVA:FOLD
This article provides general financial information about Amicus Therapeutics, Inc. under its BIVA:FOLD stock symbol. It includes sections for overview, financials, news, community, and forecasts, indicating it is likely a stub or an incomplete data page from a financial platform. The main focus is on the net current asset value per share.
[POS AM] AMICUS THERAPEUTICS, INC. SEC Filing
Amicus Therapeutics, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-3 Registration Statements with the SEC. This filing deregisters securities previously registered by Amicus, following the completion of its merger with Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin Pharmaceutical Inc., on April 27, 2026. As a result of the merger, Amicus is now a wholly owned subsidiary of BioMarin, and all previous offerings and sales of securities under the Registration Statements have been terminated.
BioMarin completes $4.8B acquisition of Amicus Therapeutics
BioMarin Pharmaceutical Inc. has completed its acquisition of Amicus Therapeutics for $4.8 billion, expanding its portfolio of rare disease therapies to include treatments for Fabry and Pompe diseases. The acquisition adds two commercial treatments and one investigational small molecule to BioMarin's offerings, strengthening its market presence and diversifying its growth profile.
BioMarin acquisition cashes out Amicus (FOLD) director’s shares and options
Amicus Therapeutics director Michael Raab disposed of all his equity, including common stock, restricted stock units, and fully vested stock options, as part of the company's acquisition by BioMarin Pharmaceutical. All of these holdings were cancelled and converted into cash at $14.50 per share, with his post-transaction holdings showing zero shares and options. This transaction reflects the standard settlement of equity in a merger, rather than an open-market sale.
Amicus Therapeutics (FOLD) CEO disposes 1.0M shares, options in BioMarin merger
Amicus Therapeutics CEO Bradley L. Campbell has disposed of over 1 million shares and several stock options in connection with BioMarin Pharmaceutical's acquisition of Amicus. The disposition includes both common stock shares and restricted stock units, which vested fully at the merger's closing. All stock options were cancelled and converted into cash payments based on the $14.50 per share merger price.
Amicus Therapeutics (FOLD) CFO exits equity as BioMarin acquisition closes
Amicus Therapeutics CFO Simon N.R. Harford has disposed of all his equity in the company following its acquisition by BioMarin Pharmaceutical Inc. This included 143,595 common shares returned at $14.50 per share and the cancellation of various stock options, which were converted into cash payments. Harford now holds zero directly owned common shares and no outstanding stock options in Amicus Therapeutics.
BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share
Amicus Therapeutics director Burke W. Whitman reported a full disposition of his equity, totaling 118,598 shares of Common Stock at $14.50 per share, as part of the acquisition by BioMarin Pharmaceutical Inc. This transaction included both common shares and restricted stock units that vested upon the merger's close. Additionally, fully vested stock options were cancelled and converted into a cash payment based on the difference between the $14.50 merger price and their exercise price, leaving Whitman with no remaining Amicus common stock or options.
Amicus (FOLD) chief legal officer exits equity as BioMarin buyout pays $14.50
Amicus Therapeutics' Chief Legal Officer, Ellen Rosenberg, divested all her equity in the company, including 463,898 directly held shares and 15,000 indirectly held by her spouse, as part of BioMarin Pharmaceutical Inc.'s acquisition of Amicus at $14.50 per share. Her stock options were cancelled and converted into cash based on the difference between the merger price and their exercise prices, leaving her with no remaining holdings in Amicus. This disposition is a routine outcome in an all-cash takeover.
Amicus Therapeutics (NASDAQ: FOLD) director’s shares and options cashed out in BioMarin deal
Amicus Therapeutics director Craig A. Wheeler disposed of all his equity—including 84,631 common shares and various stock options—in connection with the company's acquisition by BioMarin Pharmaceutical Inc. at $14.50 per share. All shares and fully vested options were converted into cash rights, reflecting a complete payout of his Amicus holdings due to the merger. This transaction is noted as a result of the change of control rather than an open-market trading decision.
Amicus Therapeutics (FOLD) CPO equity fully cashed out at $14.50 deal price
Amicus Therapeutics' Chief People Officer, David Michael Clark, disposed of all his equity in the company, including common stock, restricted stock units, and fully vested stock options, as part of BioMarin Pharmaceutical's acquisition of Amicus at a deal price of $14.50 per share. This full cash-out of equity holdings resulted in zero remaining direct holdings for Clark, consistent with a merger-related transaction rather than open-market trading. The Form 4 filing details the mechanical conversion of shares and options into cash based on the acquisition price and options' exercise prices.
[POS AM] AMICUS THERAPEUTICS, INC. SEC Filing
Amicus Therapeutics, Inc. filed Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-252566 and other S-3 registration statements following its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., on April 27, 2026. As a result of the merger, Amicus Therapeutics, Inc. is now a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., and all offerings and sales of securities under the listed registration statements have been terminated. The filing formally removes unsold securities from registration.
Amicus Therapeutics (NASDAQ: FOLD) taken private in $14.50-per-share cash merger
Amicus Therapeutics has completed its merger with BioMarin Pharmaceutical, becoming a wholly owned subsidiary. Each share of Amicus common stock was converted into the right to receive $14.50 in cash. The company will delist from Nasdaq and terminate its SEC reporting obligations, and all previous directors and executive officers have resigned.
CIBRA Capital Increases Amicus Therapeutics Holdings – April 2026 SEC Filing - News and Statistics
CIBRA Capital Ltd significantly increased its stake in Amicus Therapeutics by purchasing 1,476,861 shares, valued at $21.17 million. This transaction represents a 10.2% change in CIBRA Capital's reportable assets under management, bringing their total holdings to 1,687,661 shares worth $24.40 million. Amicus Therapeutics, a biotechnology firm specializing in rare diseases, has seen its stock deliver a 103.7% one-year total return, outperforming the S&P 500.
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects
Amicus Therapeutics (FOLD) is garnering investor interest due to recent positive share price performance and its rare disease portfolio. Analysts currently peg its fair value at $14.50, which is closely aligned with its current trading price of $14.46, suggesting it is slightly undervalued. The company's growth prospects are driven by expanding patient identification for Fabry and Pompe diseases, although potential risks from new competitors or pricing pressures exist.
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects
Amicus Therapeutics (FOLD) has garnered investor attention due to recent positive share price performance and its rare disease portfolio, particularly for Fabry and Pompe diseases. The stock is currently trading near its analyst target of $14.50, which suggests it is undervalued. The company's valuation is driven by expanding patient identification and diagnostic pathways in rare diseases, which are expected to lead to sustained revenue growth.
FOLD Price Today: Amicus Therapeutics, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock information for Amicus Therapeutics, Inc. (FOLD), including its live price chart, key market data, and recent performance. It details how to buy FOLD stock on MEXC and offers an overview of the company, its industry, and frequently asked questions regarding its financials and market classification.
BioMarin receives French clearance for Amicus merger, closing expected soon
BioMarin Pharmaceutical Inc. has received French regulatory clearance for its merger with Amicus Therapeutics, satisfying the final condition for the transaction. The merger is now expected to close on April 27, 2026, with BioMarin showing strong financial health for the acquisition. This development follows recent news for BioMarin, including board changes, strategic decisions on drug development, and analyst ratings.
French approval clears way for Amicus (NASDAQ: FOLD) merger with BioMarin
Amicus Therapeutics (NASDAQ: FOLD) has received French regulatory clearance for its merger with BioMarin Pharmaceutical, satisfying the final major condition for the acquisition. The merger, under which Amicus will become a wholly-owned subsidiary of BioMarin, is now expected to close on April 27, 2026. This development removes a significant hurdle, though the companies note that forward-looking statements are subject to various risks and uncertainties.
Amicus receives French FDI clearance, merger with BioMarin set to close April 27, 2026
Amicus Therapeutics has received French foreign investment clearance for its merger with BioMarin, satisfying a key condition of the merger agreement. The companies anticipate the deal to officially close on April 27, 2026. This clearance marks the final condition met, other than standard closing-time conditions.
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia
BioMarin Pharmaceutical has announced its intention to acquire Amicus Therapeutics for $4.8 billion, aiming to strengthen its rare disease treatment portfolio. Amicus Therapeutics, with operations in Philadelphia, specializes in treatments for rare genetic disorders and would significantly expand BioMarin's therapeutic offerings, particularly in Pompe disease. The acquisition is expected to create a leading global rare disease company with a broader pipeline and enhanced market position.
Amicus Therapeutics stock hits 52-week high at $14.48
Amicus Therapeutics (FOLD) stock reached a 52-week high of $14.48, reflecting a 104% increase over the past year due to strong investor confidence, 20% revenue growth, and 88.5% gross profit margins. The company's financial health has considerably strengthened, and analysts predict profitability this year. This surge coincides with the approval of its acquisition by BioMarin Pharmaceutical and upcoming presentations of new data on its rare disease treatments.
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia
This article is a placeholder with a title indicating that California biotech BioMarin will acquire Amicus Therapeutics, a rare-disease company with ties to Philadelphia, for $4.8 billion. The content of the article itself is missing, showing only "MSN". More information would be needed to provide a full summary of the acquisition details, reasons, and potential impacts.
How Amicus Therapeutics Inc. (FOLD) Affects Rotational Strategy Timing
Amicus Therapeutics Inc. (FOLD) shows neutral near and mid-term readings but a positive long-term bias, according to AI models. The analysis highlights a 32.5:1 risk-reward setup targeting a 9.3% gain with minimal risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis for FOLD.
Amicus Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Amicus Therapeutics recently underwent a stock evaluation revision due to mixed technical performance, despite showing significant annual returns of 109.57%, outperforming the S&P 500. The stock is currently priced at $14.46, with technical indicators presenting a mixed outlook, including bullish moving averages and mixed signals from MACD, Bollinger Bands, KST, and Dow Theory. Over three years, the stock returned 26.84%, showcasing its resilience within the pharmaceuticals and biotechnology sector.
Massachusetts Financial Services Co. MA Has $1.79 Million Position in Amicus Therapeutics, Inc. $FOLD
Massachusetts Financial Services Co. MA significantly reduced its stake in Amicus Therapeutics by 96.6% in Q4, now holding 125,524 shares valued at $1.79 million. This comes as CEO Bradley L. Campbell also sold a substantial number of shares. Amicus Therapeutics reported Q4 revenue of $185.21 million, exceeding estimates, but missed EPS expectations, and the stock currently holds an average "Hold" rating from analysts with a consensus target price of $15.39.
Amicus Therapeutics (NASDAQ:FOLD) Share Price Crosses Above 200 Day Moving Average - Here's What Happened
Shares of Amicus Therapeutics (NASDAQ:FOLD) have crossed above their 200-day moving average, trading as high as $14.46. The company recently reported Q1 earnings, missing EPS estimates but exceeding revenue expectations with a 23.7% year-over-year increase. Despite recent downgrades from several brokerages, the stock holds an average "Hold" rating and an average price target of $15.39 among analysts.
Amicus Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amicus Therapeutics, Inc. has seen a revision in its stock evaluation following a strong market performance, achieving a 122.12% return over the past year, significantly outperforming the S&P 500. Despite mixed technical indicators, the small-cap biotechnology company has maintained stability within a defined price range, demonstrating resilience. Its current stock price is $14.46, with a 52-week high of $14.48 and a low of $5.51.
Amicus Therapeutics Hits New 52-Week High of $14.48
Amicus Therapeutics, Inc. has reached a new 52-week high of $14.48, marking a 43.88% increase over the past year, outperforming the S&P 500. The company, a small-cap player with a market capitalization of USD 4,512 million, has a manageable debt-to-equity ratio of 0.59. Despite its strong stock performance, Amicus Therapeutics is currently operating at a loss, as indicated by a negative return on equity of -5.36%.
Amicus Therapeutics stock hits 52-week high at 14.46 USD By Investing.com
Amicus Therapeutics (FOLD) stock reached a 52-week high of $14.46, reflecting strong performance and investor confidence. The company has a market cap of $4.54 billion and an 88.5% gross profit margin, with analysts predicting profitability this year. Recent developments include shareholder approval of its acquisition by BioMarin Pharmaceutical and upcoming presentations on Fabry and late-onset Pompe disease treatments.
